How Many People in the UK Are on Weight Loss Injections? (October 2026)

01 · The core answer

The honest answer: a lot of people, and no exact count

The honest answer to how many people in the UK are on weight loss injections is that nobody can give you a precise, current figure. The number you see in headlines usually comes from a survey that asked adults whether they currently use, or have recently used, a weight loss medicine. Those surveys are useful for direction and scale, but they differ in who they asked, when they asked and what counted as "using". That is why one outlet reports a figure that sounds quite different from another.

Use has grown rapidly. A substantial share of it is private, because NHS access is being phased in over several years. Mounjaro, the brand name for tirzepatide, is among the best-known products. If you want the wider picture, our guides on how many people are on weight loss drugs in the UK and what percentage of people are on weight loss drugs go into the sources in more detail.

02 · Your decision

Is the headcount relevant to you?

The headcount is interesting context, but it is not a reason to start or avoid treatment. Whether a weight loss injection is right for you depends on your health, your weight-related conditions and your goals. Mounjaro is a once-weekly prescription medicine licensed in the UK for weight management in adults and for type 2 diabetes.¹ It is used alongside a reduced-calorie diet and increased physical activity, and individual results vary.

Two questions matter more than the national total. Do you meet the licensed criteria? And would you prefer to wait for NHS access or consider regulated private treatment? On the NHS side, NICE recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition, and the primary-care rollout began in June 2025 with the highest-need groups first.⁴⁶ Full rollout is expected to take years.

03 · Next step

What to do next

If you are thinking about treatment, start with a free online consultation: a GPhC-registered prescriber reviews your answers, and unsuitable orders are refunded automatically. You can see current options on our weight loss clinic page.

Many people read about usage figures, decide the time is not right, and that is a perfectly reasonable outcome.

04 · Why counts differ

Why estimates of UK use differ so much

Estimates of UK use differ because there is no single database that captures every prescription, every private order and every course started and stopped. When you see a large figure in a news story, it is typically built from one of a few kinds of evidence, each with its own blind spots.

The first kind is the population survey. Researchers ask a sample of adults whether they currently use or recently used a weight loss medicine, then scale the answer up to the whole adult population. This gives a broad sense of scale, but the answer depends heavily on the wording of the question, the sample, and whether people are comfortable admitting use. A survey that asks about "currently using" will produce a different result from one that asks about "ever used" or "used in the past year".

The second kind is NHS prescribing data. This is more precise, but it only covers what is prescribed through NHS services. Because NHS access is being phased in over several years, with the primary-care rollout beginning in June 2025 and the highest-need groups first, NHS data will understate total use in the country.⁶ It also mixes people treated for type 2 diabetes with people treated for weight management, which are different groups.

The third kind is private supply. Regulated online and high-street pharmacies dispense prescriptions to people paying themselves. There is no central public tally of those prescriptions, so private use is estimated rather than counted. This is a major reason why headline figures vary.

The fourth issue is definition. Does "weight loss injection" include only medicines licensed for weight management, or also diabetes medicines used for the same purpose? Does it include daily injections like liraglutide as well as once-weekly pens? Does a person who tried it briefly and stopped still count? Each choice shifts the total.

For you as a reader, the practical takeaway is to treat any single number with caution. Look at who produced it, when, and what exactly was counted. A good estimate states its method. A weak one simply states a large figure. If a page gives you a precise count with no method behind it, be sceptical.

It is also worth remembering that the number of people using a medicine tells you about demand and access, not about whether it suits any individual. A medicine can be widely used and still be wrong for a particular person, which is exactly why a prescriber review exists. Our related guide on how many people are using GLP-1 covers this wider class of medicines.

05 · NHS and private access

NHS and private access: how use is split

Use of weight loss injections in the UK is split between NHS prescribing and private supply, and the balance is shifting as NHS access expands. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

That phasing has a direct effect on the numbers. Because the NHS starts with the highest-need groups, many adults who would be eligible in principle are not yet reachable through their GP. Some wait. Others look at private options. A person with a BMI of 30 and no weight-related conditions, for example, may be within the licence for weight management but outside the early NHS groups.

Private supply works differently. A regulated online pharmacy asks you to complete a health questionnaire, and a GPhC-registered prescriber reviews it before anything is dispensed. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Medicine is supplied through official LillyDirect supply, direct from Eli Lilly's UK distribution.

It matters which route you use. A regulated pharmacy is registered with the General Pharmaceutical Council and appears on its public register; ours is GPhC 9012878. Unregulated sellers, by contrast, may offer to supply without a consultation or prescription, which is a warning sign. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme for reporting problems.⁷

So when someone asks how many people are on weight loss injections, the more useful follow-up is: through which route? NHS users are counted in health service data, private users largely are not, and unregulated use is invisible by definition. That last group is the safety concern, and it is another reason a plain headcount can mislead.

If you are weighing NHS against private, the honest summary is this. The NHS route costs the standard prescription arrangements but may involve a wait that depends on where you live and how you are prioritised. The private route is faster to start but you pay for the medicine. Neither is wrong; they suit different circumstances. For regional context, see our page on weight loss injections in Hereford.

06 · With or without diabetes

Weight loss injections for people with and without diabetes

Weight loss injections are used by people with type 2 diabetes and by people without it, and the two groups are treated differently. This distinction is one reason usage counts are confusing, because the same medicine can appear in diabetes statistics and in weight management statistics.

Mounjaro is licensed in the UK both for weight management in adults and for type 2 diabetes.¹ In type 2 diabetes it improves blood sugar control (HbA1c) and supports weight loss.⁸ If you have type 2 diabetes, treatment and monitoring are coordinated differently, so tell your prescriber and your usual diabetes team so care stays joined up.

For people without diabetes, the licence is for weight management alongside a reduced-calorie diet and increased physical activity. The usual starting point is a conversation about your weight, any weight-related conditions and your history. NICE guidance for the NHS recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition.⁴ Private prescribing follows the licence, which is broader than the NHS criteria, and your prescriber decides whether it is suitable for you.

There is one practical point worth stating clearly. If you take other glucose-lowering medicines, particularly insulin or sulfonylureas, doses may need adjusting because of the risk of low blood sugar. That is a conversation for your prescriber and diabetes team; it does not mean treatment is ruled out.

Why does this matter for the headline question? Because a figure for "people on weight loss injections" can quietly include people whose main reason for treatment is diabetes. Equally, a diabetes prescribing figure includes people who were never prescribed for weight. When comparing statistics, check which group is being counted.

It also matters for fairness of expectation. Someone with type 2 diabetes starting a GLP-1 type medicine is managing a condition with a monitoring plan. Someone without diabetes starting for weight management follows a titration plan and regular reviews. Both are legitimate; they are simply different pathways with different follow-up.

If you are unsure which group you fall into, the consultation questionnaire is designed to capture exactly this. Be complete and accurate about conditions and medicines, because the prescriber relies on it. Our NHS-sourced overview of the medicine is also a useful neutral read.⁵

07 · Which injections are used

Which injections people in the UK are using

The weight loss injections most commonly discussed in the UK are Mounjaro (tirzepatide), Wegovy (semaglutide) and liraglutide products such as Saxenda, and they differ in how often you inject and how they work. Knowing the differences helps you read usage statistics sensibly.

Mounjaro is a once-weekly injectable prescription medicine made by Eli Lilly. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.

Wegovy is semaglutide, a single-action GLP-1 medicine. Its pens are 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg once weekly, stepping up after at least four weeks and reaching the 2.4mg maintenance dose from week 17.¹⁸ The 2.4mg dose is the licensed maintenance dose for weight management.

Liraglutide, sold as Saxenda and in other products, is supplied at a concentration of 6mg per millilitre. It is a daily injection, unlike once-weekly Mounjaro and Wegovy.

Tablets are also now part of the picture: Wegovy tablets (oral semaglutide) and Foundayo (orforglipron) are licensed in the UK, but they are different medicines from Mounjaro.

Why does this matter when thinking about numbers? Because a survey that asks about "weight loss injections" may capture people on any of these, and each has a different dosing pattern, different evidence and different cost. A daily injection is a different daily experience from a weekly one. A person who tried one product, switched, and now uses another may be counted once or twice depending on the survey.

It also matters when you compare. If you want to understand uptake of one product specifically, our guides on how many people are on Mounjaro and how many people are taking Mounjaro focus on it.

08 · Safety and the downsides

Safety, downsides and the worry about harm

Weight loss injections are prescription medicines with real side effects, and the right way to judge safety is through regulators and your prescriber, not through how many people use them. Weight loss injections carry known risks, which is why they are supplied only after a prescriber review.

The commonest early effects are mild nausea, altered appetite and tiredness in the first days after each injection, and they usually settle.¹ Experiences differ widely. Some people notice appetite change in the first week; others feel little until a higher dose, and both are normal. Seek immediate medical help for severe, persistent stomach pain that may spread to your back, with or without vomiting; pain in the upper right abdomen, fever or yellowing of the skin or eyes; or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.

Regulators actively monitor this class of medicine. The European Medicines Agency's safety committee reviewed a signal about suicidal ideation with GLP-1 receptor agonists, and the MHRA runs the Yellow Card scheme, where patients and professionals can report suspected side effects.¹⁷¹⁹ If you notice a new symptom after starting, tell your prescriber and consider a Yellow Card report. This is how safety knowledge grows.

If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night. Tell your prescriber about any change in your mood while taking Mounjaro.

Medicines interact with other things in your life. Mounjaro can reduce absorption of oral contraceptives because stomach emptying slows, so talk to your prescriber about contraception.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ If you use insulin or sulfonylureas, doses may need adjusting because of the risk of low blood sugar.

The biggest avoidable risk is where you get the medicine. Counterfeit and unregulated products circulate, and sellers who offer to supply without a consultation or prescription are a red flag. The MHRA publishes alerts, and you can check that a pharmacy is on the GPhC register.⁷ Genuine Mounjaro KwikPens come through official supply; ours come direct from Eli Lilly's UK distribution through LillyDirect.

As for the downside of taking them: side effects, the need for ongoing review, the cost for those paying privately, and the reality that weight can return after stopping. Treatment works alongside diet and activity, not instead of them. A good prescriber will talk through these honestly before you start, and they remain available for monthly reviews while you are on treatment.

09 · Results and keeping weight off

Results, pace and keeping weight off afterwards

Results on weight loss injections are gradual, they vary between people, and keeping weight off after stopping is a genuine challenge to plan for. Popularity says nothing about what you personally should expect.

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² As a worked example only, for someone starting at 100 kg, 20.9% is about 21 kg. Trial averages do not predict your own result.

Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month. Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend, not individual weigh-ins.² Early loss includes water weight, so the trend matters more than any single weigh-in.

Treatment response is reviewed by your prescriber. If you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.

What about keeping weight off? In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average.¹⁴ Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system, and there is no way to speed this up.

Planning for the long term is therefore part of the decision.

Keep realistic expectations about pace, and use the first weeks to learn how your body responds rather than to chase the scale.

10 · Cost and affording treatment

How people afford weight loss injections

People afford weight loss injections by using the NHS where they qualify, or by paying privately and spreading or planning the cost across the year. Because NHS access is being phased in over several years, many adults who meet the licensed criteria consider the private route, so cost is a real part of the picture.

It helps to understand the shape of the cost. Mounjaro is supplied in pens, each containing four weekly doses, so you buy roughly one pen after at least four weeks. Everyone starts on 2.5mg, then steps up at a minimum of four-week intervals depending on response and tolerance. That means the early months involve a sequence of different pens. At standard prices, the first four pens (2.5mg, 5mg, 7.5mg, 10mg) cost £959.96. A new customer's first order is £40 less with code FIRST40, and every later order is £25 less (code DOSE25).

A first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg, at standard prices. Many people settle at a maintenance dose of 5mg, 10mg or 15mg, but higher is not automatically better, and your prescriber guides the pace. For other maintenance doses, the monthly standard prices are £279.99 for 7.5mg, £290.99 for 10mg and £319.99 for 12.5mg.

To give market context, across the UK pharmacies we track, Mounjaro pens ranged from £143.96 to £339.00 per month across all doses as of our index check on 10 October 2026, and the gap between providers for the same dose ranged from £27 to £41. Comparing the dose you actually need, not just the headline starting price, is sensible.

Practical ways people manage cost include: choosing a regulated provider with transparent pricing; using a new-customer or reorder discount; and using payment options. We accept Visa and Mastercard, Klarna and pay-monthly options, and there are no subscriptions. Repeat orders re-check suitability, with no auto-shipping.

One caution matters more than any saving. Very cheap offers from unregulated sellers may be counterfeit, and sellers who offer to supply without a consultation or prescription should be avoided.⁷ A safe supply chain is worth more than a small saving.

How ordering works with us is straightforward. First, complete a free online consultation; there is no charge and no obligation. Second, a GPhC-registered prescriber reviews your answers. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Third, we dispense and dispatch, with same-day dispatch when ordered by 3pm, and free next-day tracked delivery in discreet, temperature-controlled packaging. Needles, a sharps bin and injection guidance come with every order. You can start from the Mounjaro pen page.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹